Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 3/20 | 0.38 |
| ▸ | AURKC | Q9UQB9 | 3/20 | 0.38 |
| ▸ | PLK4 | O00444 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3644098 | 0.81 | AURKA (0.41) | SMN1; SMN2RAB9AMAPTAURKBSRC | |
| SCHEMBL3644101 | 0.81 | AURKA (0.41) | SMN1; SMN2RAB9AMAPTAURKBSRC | |
| SCHEMBL10063714 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL2960111 | 0.80 | AURKA (0.55) | SMN1; SMN2RAB9AMEN1KMT2AMAPT | |
| SCHEMBL10294671 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL375438 | 0.78 | AURKB (0.47) | AURKBSRCGSK3BABL1AURKA | |
| SCHEMBL10294808 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2RAB9ANPC1MAPTAURKB | |
| SCHEMBL10295038 | 0.77 | CHKA (0.49) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL13004560 | 0.77 | AURKA (0.60) | AURKBSRCABL1AURKAAURKC | |
| SCHEMBL10294761 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9ANPC1AURKBSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917259-B1 | PYRAZINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-1917259-B1 | PYRAZINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7989456-B2 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989456-B2 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989456-B2 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-02 | — | — | US | disclosed |
| US-20100222367-A1 | PYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222367-A1 | PYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222367-A1 | PYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-02 | — | — | US | disclosed |
| US-7737151-B2 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737151-B2 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737151-B2 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070173516-A1 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-26 | — | — | US | disclosed |
| US-20070173516-A1 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-26 | — | — | US | disclosed |
| US-20070173516-A1 | Pyrazine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-26 | — | — | US | disclosed |
| WO-2007022384-A2 | PYRAZINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222367-A1 | PYRAZINE KINASE INHIBITORS | MAP3K5, MAP3K20, MAP3K1 | SMN1; SMN2 2735/4885RAB9A 2261/4885NPC1 2247/4885 |
| US-20070173516-A1 | Pyrazine kinase inhibitors | MAP3K5, MAP3K20, MAP3K1 | SMN1; SMN2 2735/4885RAB9A 2261/4885NPC1 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.